Envestnet Asset Management Inc. lowered its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Rating) by 24.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 20,438 shares of the medical equipment provider’s stock after selling 6,706 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Lantheus were worth $1,350,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Truist Financial Corp purchased a new stake in Lantheus in the first quarter worth about $283,000. Mutual of America Capital Management LLC grew its holdings in Lantheus by 5.5% in the first quarter. Mutual of America Capital Management LLC now owns 9,754 shares of the medical equipment provider’s stock worth $539,000 after purchasing an additional 505 shares during the period. State of New Jersey Common Pension Fund D purchased a new stake in Lantheus in the first quarter worth about $4,828,000. Versor Investments LP purchased a new stake in Lantheus in the first quarter worth about $332,000. Finally, ClariVest Asset Management LLC purchased a new stake in Lantheus in the first quarter worth about $1,128,000. Hedge funds and other institutional investors own 98.14% of the company’s stock.
Insider Activity at Lantheus
In other Lantheus news, insider Etienne Montagut sold 2,536 shares of Lantheus stock in a transaction on Tuesday, October 18th. The stock was sold at an average price of $73.41, for a total transaction of $186,167.76. Following the completion of the sale, the insider now directly owns 81,999 shares of the company’s stock, valued at approximately $6,019,546.59. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Lantheus news, COO Paul Blanchfield sold 2,432 shares of Lantheus stock in a transaction on Thursday, November 17th. The stock was sold at an average price of $54.79, for a total transaction of $133,249.28. Following the completion of the sale, the chief operating officer now directly owns 73,968 shares of the company’s stock, valued at approximately $4,052,706.72. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Etienne Montagut sold 2,536 shares of Lantheus stock in a transaction on Tuesday, October 18th. The shares were sold at an average price of $73.41, for a total value of $186,167.76. Following the sale, the insider now directly owns 81,999 shares of the company’s stock, valued at $6,019,546.59. The disclosure for this sale can be found here. Insiders sold a total of 68,530 shares of company stock worth $5,187,928 in the last quarter. 1.60% of the stock is owned by company insiders.
Analysts Set New Price Targets
Lantheus Price Performance
LNTH opened at $57.38 on Tuesday. The business has a fifty day moving average of $68.93 and a 200 day moving average of $70.28. Lantheus Holdings, Inc. has a 52-week low of $23.51 and a 52-week high of $87.47. The company has a quick ratio of 1.98, a current ratio of 2.13 and a debt-to-equity ratio of 0.24. The stock has a market cap of $3.95 billion, a P/E ratio of 38.51 and a beta of 0.79.
Lantheus (NASDAQ:LNTH – Get Rating) last posted its quarterly earnings data on Thursday, November 3rd. The medical equipment provider reported $0.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.75 by $0.15. Lantheus had a return on equity of 37.77% and a net margin of 13.35%. The company had revenue of $239.29 million during the quarter, compared to analysts’ expectations of $228.52 million. As a group, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 3.51 EPS for the current year.
Lantheus Company Profile
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.
- Get a free copy of the StockNews.com research report on Lantheus (LNTH)
- Three Ways To Win The Online Gambling Industry
- Santa Claus Rally? Here’s What Needs to Happen
- Will the Return of Bob Iger Return the Magic to Disney Stock?
- Is Ardelyx is A Buy After Slip in Early 2022
- Is Tesla A Bargain Now As It Trades At Two-Year Lows?
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.